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This present observational, longitudinal, and non-concurrent study was developed with the purposes of 
evaluate the profile of patients attended by a pharmacotherapeutic follow-up service and describe the 
Drug-Related Problems (DRPs) found over there; determine the proportion of DRPs between the health 
problems presented by the studied population, classifying them and identifying the situations related with 
their appearance. The study was developed at the School Pharmacy of Newton Paiva University Center, 
Belo Horizonte, MG, during the period from 2001 November up to 2003 November. Ninety seven patients 
have been evaluated, the majority of female sex (66.0%), with up to 8 years of scholarship (45.4%), mean 
age of 56.7 ± 13.0 years; mean of 4 ± 2 diagnosed diseases; 7 ± 6 complaints and 4 ± 2 medications per 
patient. Nine hundred and twelve health problems have been identified: 56.5% uncontrolled. From the 
uncontrolled problems, 380 (73.6%) were DRPs and between these, 81 (21.3%) were risks for DRP. 
From the 97 followed-up patients, 89 (91.7%) have presented at least one DRP during the follow-up. The 
more frequent DRPs were related to effectiveness (53.2%), to necessity (25.2%) and to safety (21.6%). 
A great number of uncontrolled problems was observed, as well as the possibility to resolve them by 
means of pharmaceutical care, indicating so the resolutive potential of this practice.
Uniterms: Pharmaceutical care. Pharmacotherapeutic follow-up. Drug Related Problem (DRP).
O presente estudo observacional, longitudinal, não concorrente teve por objetivos avaliar o perfil dos 
pacientes atendidos por um serviço de acompanhamento farmacoterapêutico e descrever os ‘problemas 
relacionados com medicamento’ (PRM) encontrados; determinar a proporção de PRM dentre os problemas 
de saúde apresentados pela população estudada, classificá-los e identificar situações relacionadas com 
seu surgimento. O estudo foi realizado na Farmácia Escola do Centro Universitário Newton Paiva, em 
Belo Horizonte, MG, durante o período de novembro de 2001 a novembro de 2003. Foram avaliados 97 
pacientes, maioria mulheres (66,0%), com até 8 anos de escolaridade (45,4%), média de idade de 56,7 ± 
13,0 anos; média de 4 ± 2 doenças com diagnóstico; 7 ± 6 queixas e 4 ± 2 medicamentos por paciente. 
Foram identificados 912 problemas de saúde: 56,5% não controlados. Dos problemas não controlados, 
380 (73,6%) eram PRM e desses 81 (21,3%) eram riscos de PRM. Dos 97 pacientes acompanhados 89 
(91,7%) apresentaram pelo menos um PRM durante o acompanhamento. Os PRMs mais freqüentes foram 
relacionados à efetividade (53,2%), à necessidade (25,2%) e à segurança (21,6%). Observou-se grande 
número de problemas não controlados e a possibilidade de resolvê-los por meio da atenção farmacêutica, 
demonstrando o potencial resolutivo dessa prática.
Unitermos: Atenção farmacêutica. Acompanhamento farmacoterapêutico. Problemas Relacionados 
com Medicamentos (PRM).
INTRODUCTION
The pharmaceutical care (PC) is considered as a 
change in the profession conception and has arisen at the 
beginning of 90’s in the United States. With the intention to 
adapt the concept initially proposed by Heppler & Strand 
(1990) to national reality, it was elaborated the Brazilian 
Consensus of Pharmaceutical Care (Consenso Brasileiro 
de Atenção Farmacêutica), which defines the pharma-
ceutical care as a conjunction of activities in which the 
pharmacist interacts directly with patients; between these 
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activities are the dispensation, the health education, the 
pharmaceutical orientation, and the pharmacotherapeutic 
follow-up (Pan American Health Organization; 2002).
The pharmaceutical care has arisen and is spreading 
itself as a result of numberless works showing an important 
increase of both, morbimortality and health costs, which 
is due to the use of medicine. The adverse reactions have 
been considered the fourth death cause at United States, 
losing only for cardiovascular diseases, cancer, and cere-
brovascular accident (Johnson, Bootman; 1995). Ernst, 
Grizzle (2001) have verified also, in that same country, an 
annual cost of 177.4 billion dollars related with this kind 
of morbimortality in outpatients.
As referred by Strand (1990), the main purpose for 
all healthcare professionals is to improve the patients’ qua-
lity of life, being that every professional contributes with 
his/her specific practice. This way, pharmaceutical care 
can contribute to assure the outcome of pharmacological 
therapy, once it presupposes three main responsibilities 
in the clinical context: 1) to meet patients’ necessities 
respecting to pharmacotherapy, that is, to assure that 
patients requiring a medication utilize it, that the used 
pharmacotherapy is the most effective available one, the 
most safe possible one, and that it can be used as indicated; 
2) to identify, resolve, or prevent any problem related to 
pharmacotherapy, which could interfere with the above 
described pharmacotherapeutic necessities; 3) to assure 
that treatment goals and optimal results are reached. The-
refore, during his/her practice, the pharmacist shall be able 
to determine if the necessities described by patients are not 
being met and, in this case, translate them into drug related 
problems, proposing then interventions that are able to 
resolve these necessities (Cipolle et al., 2004; Consenso, 
1999; Espejo et al., 2002).
This work had as purposes to evaluate the profile 
of patients attended by a pharmacotherapeutic follow-up 
service, and describe the drug related problems found in 
this group of patients, and reported by the pharmacists 
developing the follow-up; to determine the proportion of 
drug related problems (DRPs) between the health proble-
ms presented by the studied population, classify the DRPs 
according to categories professed by the Second Consen-
sus of Granada respecting Drug Related Problems (2002), 
and identify the situations leading to appearance of a DRP.
POPULATION AND METHODS
This is an observational, longitudinal, and non-con-
current study developed at School Pharmacy of Newton 
Paiva University Center (FECUNP), Belo Horizonte, in 
the period between 2001 November and 2003 November. 
It was a pharmacy placed in a middle class neighborhood, 
beside the Faculty, and also close to a great community 
of low acquisitive power, named Morro das Pedras. This 
way, the pharmacy possesses three different kinds of pu-
blic: students, University Center employees and teachers, 
neighborhood dwellers, and residents of the referred com-
munity. The patients candidate to pharmacotherapeutic 
follow-up service were, in their majority, dwellers of Mor-
ro das Pedras, but neighborhood patients and university 
center employees have also been followed-up. The offered 
service was unpaid. 
All patients submitted to pharmacotherapeutic 
follow-up, who entered in the service up to 2003 May and 
agreed to participate were considered eligible for the study. 
It was developed an initial anamnesis and the obtained data 
were recorded into a follow-up card. 
Only follow-up cards from patients who agreed to 
participate and signed an informed consent were included; 
the patients that did not agree to participate did not suffer 
any disservice in their follow-up, as well. The data have 
been presented aggregately, without the identification 
of any patient. The work has been submitted to Institu-
tional Review Board/Independent Ethics Committee of 
the Federal University of Minas Gerais (UFMG), being 
opportunely approved.
In the service, the real problems related to pharma-
cological therapy (DRP) and the other health problems 
(HP) were identified, classified and ordered according the 
priority for resolution. The risks for DRP, in the studied 
population, have also been identified. For every health 
problem identified, pertinent goals and interventions have 
been drawn. New problems reported by participants were 
being recorded, classified and resolved continuously (Uni-
versidad de Granada, 1999; Cipolle et al., 2004). 
For this study elaboration, data referring to health 
problems and complaints reported by patients were col-
lected, as well as data referring to utilized medications. In 
the first case, all the records done in the follow-up cards 
up to 2003 May were used; yet in the second case, only 
the records of the initial anamnesis were considered. A 
codification of health problems and complaints was deve-
loped from the CID 10 (WHO, 2003). For the classification 
of medications it was used the ATC system (Anatomical 
Therapeutic Chemical Classification System) (http://www.
whocc.no/atcddd).
For the identification of found problems, the data 
recorded in the follow-up cards were analyzed and recor-
ded in a data collection card. They have been classified 
as: DRP; Health problem unrelated to medication use and 
uncontrolled (HP); Controlled health problem; Informed 
health problem (defined as a vaguely informed problem, 
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without the detailing necessary for adoption of interven-
tions); Health problem under evaluation (defined as a 
problem for which an intervention had already occurred, 
being necessary to wait for the respective result).
In this work, the definition and classification of 
DRP professed by the Second Consensus of Granada 
respecting Drug Related Problems (2002) (Table I) have 
been adopted.
A descriptive data analysis has been developed, in a 
procedure that has included the determination of propor-
tion of drug related problems (DRP) between the health 
problems presented by the studied population, in a general 
way and according to professed categories. It has included 
also frequencies distribution, central trend measures and 
variability measures.
RESULTS AND DISCUSSION
Ninety seven patients were analyzed, being the 
majority of them women (66.0%), married (52.6%), with 
up to 8 years of scholarship (45.4%) and do not exerting 
any professional activity (55.7%). The mean age of par-
ticipants was 56.7 ± 13.0 years and the median 60 years 
(range 24-92 years).
Women presented the worst self-referred functional 
and health statuses, higher frequency of reports related to 
depressive symptoms and hospitalization history. In 1997 
in the United States, about 70% of hospitalized patients 
were of female sex. This way, they have also searched 
more frequently for health services, including the PC ser-
vices, varying between 59% and 76% of attended popula-
tion (Leanne, 1998; Rosenfeld, 2003; Cipolle et al., 2004). 
About 60% of studied patients presented up to eight 
years of scholarship. This is a characteristic that could 
negatively affect the formulation and comprehension 
of concepts of self care in health, besides to exert some 
influence on the necessary time as well as the employed 
vocabulary, for execution of educative actions.
The expressive number of individuals aged above 
50 years could be explained by the form of individuals 
gathering applied in this study, which initially has been 
developed by means of activities of education in health. 
This is a public more seized by chronic diseases; therefore, 
they are more worried about health, and more commonly 
look for activities subsidizing self care. The mean age 
found was compatible with the results of other PC services 
in the United States (58 years) (Leanne, 1998; Cipolle et 
al., 2004). 
Ninety six (99%) out of all followed-up patients 
reported, at least, one disease with a diagnosis done by a 
physician. Three hundred ninety six diseases have been 
reported, with an average of 4 ± 2 diseases per patient, 
median of 4 diseases (range = 0 to 11). The results of this 
study are similar to those obtained by Cipolle et al. (2004) 
that, in a study developed with 20761 patients in the United 
States, have found an average of 3 ± 2 diseases in patients 
younger than 65 years, and 5 ± 2 diseases in those older 
than 65 years. 
As expected, the more mentioned diseases corres-
ponded to the chronic ones, common in the age range 
more frequent between the participants of this study, such 
as arterial hypertension (19.7%; 78), disturbance in the 
lipoprotein metabolism (6.3%; 25) and diabetes mellitus 
(4.8%; 19).
During the follow-up, 96 patients (99%) have re-
ferred, at least, one complaint. The observed average was 
of 7 ± 6 complaints and the median was of 5 complaints 
(range = 0 to 32). The complaints were defined as signals, 
symptoms or diseases without medical diagnosis, reported 
by the patient or observed by the pharmacist. As a whole, 
674 complaints have been reported. 
The algic complaints corresponded to 30.4% of all 
reported/observed complaints in this study, comprehending 
the complaints in the osteomuscular apparatus, the heada-
ches and the pains non-classified in other parts. Carvalho 
(1999) affirms that the pain has been less valorized as a 
TABLE I – Classification of ‘Drug Related Problems’ (DRP)
Necessity Problem
Necessity DRP 1: The patient suffers from a health problem as a result of not taking the medicine that he needs.
DRP 2: The patient suffers from a health problem as a result of taking a medicine that he does not need.
Effectiveness DRP 3: The patient has a health problem resulting from a non-quantitative ineffectiveness of a medicine. 
DRP 4: The patient has a health problem resulting from a quantitative ineffectiveness of a medicine. 
Safety DRP 5: The patient suffers from a health problem as a consequence of a non-quantitative safety problem of a 
medicine.
DRP 6: The patient suffers from a health problem as a consequence of a quantitative safety problem of a medicine.
Source: SEGUNDO CONSENSO DE GRANADA SOBRE PRM, 2002
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symptom or disease, during the formation of health profes-
sionals. Such a fact reinforces the importance of pharmacists 
adequately trained for pain handling, who know exactly 
when make use of therapeutic strategies, such as OTC me-
dications, and what is the suitable moment to forward the 
patient to a physician, for more detailed evaluation; contri-
buting so to improve the quality of care provided to patients.
The other more reported complaints were ‘fatigue/
malaise’ (5.0%, 34), ‘intestinal constipation’ (4.3%, 29); 
‘sleeping disturbances’ (4.3%, 29) and ‘dizziness and 
vertigo’ (3.9%, 26). 
It is even appropriate to emphasize that 20 patients 
(20.6%) presented complaints related to ‘emotional sta-
tus or behavior’; yet 33% of patients reported ‘sleeping 
alterations’. Such data look to be coherent with those 
obtained by Szwarcwald (2004), in a published study 
about Brazilians perception respecting their own health, 
which verified that 25% of individuals reported a severe 
or very severe grade of disturbance respecting the state 
of mind (sadness or depression, worry or anxiety) and 
18% presented sleeping problems. These results could be 
evaluated based on the current social context, in which 
situations of unsafety, criminality, unemployment and 
inequality are present.
All the followed-up patients reported the use of, at 
least, one medication, totalizing 416 medications. The 
observed average of utilization was 4 ± 2 medications, 
median of 4 (range = 1 to 13). Out of this total, 338 (81.3%) 
were prescribed, 60 (14.4%) were not prescribed and for 
18 medications (4.3%) this information was not reported. 
The data found in this study were compatible with other 
published ones, being that Cipolle et al. (2004) have veri-
fied that patients younger than 65 years were making use 
of an average of 5 medications, while those older than 65 
years reported an average of 7 medications. Yet Durán 
(1999) has found an average of 6.1 medications per patient 
during six months of follow-up.
In Brazil, studies developed during the pharma-
cotherapeutic follow-up of hypertensive patients, have 
verified averages of 8.5 ± 4 medications per patient (Lyra-
Júnior et al, 2007) and 5.4 + 1.08 medications per patient 
(Souza et al, 2007).
The more utilized medications were those neces-
sary for the treatment of the most reported diseases, such 
as the medications acting on the cardiovascular system, 
corresponding to 145 (34.9%) mentions. Following, are 
described the utilized medications, classified according 
the ATC system (Table II).
TABLE II – Distribution of medications used by patients followed-up at FECUNP, from 2001 to 2003 – First and second level of 
ATC classification
Medications Frequency Percentage
Cardiovascular system 145 34.9%
Diuretics 44 10.6%
Acting over the renin-angiotensin system 31 7.5%
Beta-blockers and associations 21 5.0%
Calcium channel blockers and associations 21 5.0%
Central nervous system 86 20.7%
Psycholeptics1 28 6.7%
Analgesics 26 6.2%
Psychoanaleptics2 20 4.8%
Gastrointestinal tract and metabolism 70 16.8%
Used in diabetes 26 6.2%
Antacids and other for ulcer and flatulence 19 4.6%
Musculoskeletal system 27 6.5%
Anti-inflammatory and antirheumatic 13 3.1%
Blood and hematopoietic organs 21 5.0%
Antithrombotics 19 4.6%
Genitourinary tract 16 3.8%
Sexual/modulator hormones 15 3.5%
Hormones 16 3.8%
Thyroid treatment 14 3.4%
Other 35 8.5%
TOTAL 416 100,0%
1: 5.8% corresponding to anxiolytics; 2: 3.6% corresponding to anti-depressives.
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The medications acting on the central nervous sys-
tem corresponded to the second class of more mentioned 
medications (20.7%), which looks to point out their use 
with the purpose of relief symptoms/signals related to 
emotional status as well as sleeping disturbances and 
syndromes of cephalalgia and migraine, which if summed, 
correspond to the third more frequent group of complaints. 
Considering the previous discussion about multi-causality 
of diseases, it becomes important to evaluate the role of 
the medicalization of such disturbances, as well as to work 
with the purpose to propose changes that are shown more 
effective and/or safe for the treatment of such disturbances.
912 problems in the 97 participant patients have 
been identified, being 516 (56.5%) of them uncontrolled, 
requiring an intervention from the pharmacist. These 
problems included the health problems non-related to 
the use of medications, which presented themselves as 
uncontrolled; and the real DRPs as well. Following, the 
frequency distribution of problems according to categories 
professed in this study (Figure 1).
Yet, Table III presents a descriptive analysis of 
found problems. It is possible to perceive that the average 
of health problems reported by individuals was similar to 
the average of both, uncontrolled and DRP-type problems 
found by pharmacists during the pharmacotherapeutic 
follow-up. 
From the found problems, 380 (73.6%) were DRPs 
and between these ones, 81 (21.3%) were risks for DRP, 
that is, problems that had not appeared yet, but that had a 
good chance to occur.
Out of the 97 followed-up patients, 89 (91.7%) pre-
sented, at least, one DRP during the follow-up, 18 (18.6%) 
presented one DRP, 11 (11.3%) two DRPs, 15 (15.5%) 
three DRPs, 8 (8.2%) four DRPs, 11 (11.3%) five DRPs, 
9 (9.3%) six DRPs, and 17 (17.5%) patients presented 
more than six DRPs. It is useful to emphasize that out of 
these last 17 patients, three presented twelve DRP-type 
problems during the follow-up. The average of DRPs was 
of 4, median of 3, varying from 0 to 12 DRPs per patient.
Cipolle et al. (2004) have reported the presence, only 
at the first follow-up, of at least one DRP in 42% of follo-
wed-up patients, and that one out of every five patients 
presented multiple DRPs, in a total of 5136 followed-up 
patients. Rossinholi (2002) has identified DRPs in 54% of 
35 patients enrolled into a pilot-project for the implanta-
tion of pharmaceutical care in Curitiba. Yet, Durán (1999) 
FIGURE 1 – Distribution of health problems, per category, presented by patients followed-up at FECUNP from 2001 to 2003. 
Note 1: Uncontrolled problems.
TABLE III – Descriptive analysis of problems observed at FECUNP, 2001 to 2003
Mean ± Standard 
Deviation
Median Range
Minimum Maximum
Health problems (n=912) 9 ± 5 8 3 23
Uncontrolled problems (n=516) 5 ± 3 5 1 16
DRPs (n=380) 4 ± 3 3 0 12
Actual DRPs (n=299) 3 ± 2 3 0 10
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encountered 48 DRPs in 35 patients, corresponding to 1.8 
DRPs per patient; he verified yet that 74.3% of patients 
presented, at least, one DRP. It is possible to notice a 
higher average of DRPs in that study as compared with 
other works, but it is convenient to highlight that these 
DRPs were continuously identified and recorded along 
all the follow-up, besides to be not restricted to specific 
disturbances, as the results obtained in other publications 
of this same area (Cranor & Christensen, 2003 a,b,c; 
Hernández-Ronquillo et al., 2003).
The professional who develops the PC should be 
able to translate the patients’ necessities respecting to 
pharmacotherapy that are not being attended in DRP; and 
from that point on, delineate strategies for their resolution. 
Therein, it is very interesting the work developed by Law 
(2003), which divides the process of use of medications 
into nine steps, evaluating then the opinion of physicians, 
pharmacists, and patients respecting how these steps have 
been conducted. Only 10% of patients have identified 
problems in the described steps, however, 30% of these 
patients have done comments respecting the cost of pres-
criptions, the adequacy of therapy, the access to caretakers, 
and the convenience of treatment. These comments indi-
cate that there are important issues being neglected in the 
process of use of medications, and these issues could be 
DRP generators. The professional is in charge of develop 
their listening, comprehend such necessities and, face to a 
negative clinical result or its imminence, intervene in order 
to resolve or prevent its occurrence. So, the definition of 
the pharmacist’s role in the identification, resolution, and 
prevention of DRPs situates clearly his/her function in the 
context of global attention provided to patient.
In this study, the more frequent problems were those 
related to effectiveness of proposed treatments (Table IV). 
This is an important problem of public health, once resour-
ces are being spent for the treatment/control of diseases, 
which are not being adequately controlled. Ernst & Grizzle 
(2001) have estimated an average cost of 977 dollars for 
the treatment of therapeutic failures, and of 1,105 dollars 
for the treatment of a new health problem resulting from 
the wrong use of medications. It is convenient to empha-
size yet that these problems configure themselves as an 
important cause of morbimortality, besides to negatively 
impact the individuals’ quality of life. The identification of 
fortuitous cases of non-effectiveness, the search for their 
possible causes, and their final resolution assume then an 
essential role for the patients’ care. This is an important 
change of paradigm, once the pharmacists, traditionally, 
have focalized their actuation on problems related to me-
dications safety and, despite the obvious importance of 
such problems, those linked to the lack of effectiveness 
should also be cautiously assessed (Cipolle et al., 1998).
Even, the main problem identified was the lack of 
effectiveness of treatments for disturbances in the car-
diovascular system, corresponding to 13.8% (n=71) of 
all reports. Considering that blood hypertension was the 
most frequent problem, it is appropriate to emphasize the 
importance of constant monitoring of patients under this 
condition. The fast identification of patients who are not 
obtaining the desired effect with the professed therapeutic 
strategy allows a readdressing of this patient for the health 
service, and could contribute for a more effective control 
of the clinical picture and, possibly, contribute also for 
the decrease of morbimortality related to cardiovascular 
TABLE IV – Distribution of health problems, per category, presented by patients followed-up at FECUNP from 2001 to 2003
Diseases, disturbances and/or 
signals and symptoms
Drug Related Problems Uncontrolled 
Health Problem
TOTAL
Necessity Effectiveness Safety
Circulatory apparatus 20 (3.9%) 71 (13.8%) 7 (1.4%) 25 (4.9%) 123
Osteomuscular system 8 (1.5%) 30 (5.8%) 3 (0.6%) 23 (4.4%) 64
Endocrines, nutritionals 6 (1.2%) 25 (4.9%) 9 (1.7%) 34 (6.6%) 74
Digestive apparatus 3 (0.6%) 14 (2.7%) 14 (2.7%) 33 (6.4%) 64
Mental and behavioral1 10 (1.9%) 7 (1.4%) 9 (1.7%) 10 (1.9%) 36
Nervous system 1 (0.2%) 16 (3.1%) 1 (0.2%) 19 (3.7%) 37
Genitourinary apparatus 5 (1.0%) 3 (0.6%) 5 (1.0%) 11 (2.1%) 24
Infectious diseases2 8 (1.5%) 3 (0.6%) 0 (0.0%) 0 (0.0%) 11
Skin and subcutaneous tissues 0 (0.0%) 1 (0.2%) 2 (0.4%) 6 (1.2%) 9
Other 4 (0.8%) 3 (0.6%) 11 (2.1%) 56 (10.9%) 74
Total 65 (12.6%) 173 (33.5%) 61 (11.8%) 217 (42.1%) 516 (100%)
1: related to cognition, perception, emotional state and behavior; 2: Includes parasitic
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events. Considering the problem magnitude (about 27% 
of the obits in Brazil, reaching 37%, when excluded the 
barely defined causes and violence cases), it is a belief that 
the involvement of all health professionals in the identifi-
cation and control of this disturbance and its consequences 
would exert a great impact all over the country public he-
alth (Sociedade Brasileira de Hipertensão Arterial, 2006). 
In this study, the non-utilization of medications was 
the main cause of DRPs. Table V presents a description 
of the causes of actual DRPs and risks for DRPs found 
in this study. For some patients, the use of medications 
implies in a problem that is major than the illness itself, 
what contributes for a high rate of treatment abandon-
ment, mainly for chronic diseases requiring a treatment 
for indefinite time (Cipolle et al., 1998; Grupo de trabajo 
sobre incumplimento del Hospital Geriátrico Virgen del 
Valle; 1991; Hernández-Ronquillo et al., 2003). 
The non-utilization of medication on the part of pa-
tients, that is, the non-adherence, is a situation with high 
potential for generation of DRPs, which could be effecti-
vely worked by pharmacists at the basic attention level, by 
means of many interventions that are varied and broadly 
discussed in the literature, showing one more possibility of 
intervention of this professional in the sense of optimizing 
the results of pharmacologic therapy.
Respecting to uncontrolled health problems that 
are not related to medications, which corresponded in 
this study to 42.1% of all problems, it is appropriate to 
discuss the role of non-pharmacologic treatments, based 
on lifestyle modifications and indicated as main or supple-
mentary measure to pharmacologic treatments for several 
disturbances. In this sense, the educational strategies for 
self-care help to improve the understanding of diseases, 
proposed treatments and preventive strategies; contribu-
ting also for the correction of concepts and mistaken belie-
fs. In this way, they enable individuals to decision-making 
respecting their own health, contributing to increase the 
adhesion to treatments and favoring the control of disea-
ses (Barron-Rivera et al., 1998; Bettencourt et al., 2002; 
Norris et al., 2002). 
When a health professional discuss with his/her 
patients respecting risks decrease, diseases treatment and 
medications use, there is a higher probability for patients 
to be changing their inadequate habits, participating in 
selections, and taking their medications correctly. Con-
sidering the potential that routine advising has for the 
improvement of people’s and general public health, it is 
questionable why this practice is not more diffused (Center 
for the Advancement of Health, 2001).
However, it is necessary to emphasize that, as refer-
red by Czeresnia & Freitas (2003), the health promotion 
could be associated to preventive measures, respecting the 
physical environment and lifestyles, that is, issues that are 
under the individual control. But it is also associated to 
more complex issues that are out of individual’s control, 
and to achieve health for everybody it is necessary to 
decrease inequalities, to increase the preventive efforts 
and the people’s capacity to confront their own health 
problems. Therefore, the alterations in lifestyle could not 
be viewed as the single aspect for the health promotion, 
TABLE V – Main identified causes for DRP found at FECUNP from 2001 to 2003
CAUSE Total of DRP Risk for DRP
Frequency Percentage Frequency Percentage
Non-utilization of medication 96 25.3% 34 43.3%
Prescription in lower dose 79 20.8% 3 3.7%
Unidentified cause1 73 19.2% 21 14.8%
Refractoriness 35 9.2% 0 0
Non-prescription of required medications 35 9.2% 2 2.5%
Use of medication different than prescribed or 
inadequate use
19 5.0% 4 4.9%
Interaction 18 4.7% 9 11.1%
Lacking access to medications 18 4.7% 7 8.6%
Prescription in higher dose 6 1.6% 0 0
Ignored 1 0.3% 0 0
Total 380 100.0% 81 100.0%
1: Referred to cases of adverse reactions with undefined cause (n=61) and to cases of DRP 2, due to the use of unnecessary 
medications (n=12). 
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being risky to attribute only to the patient, all responsibility 
for his/her own health.
Even, respecting to detected problem, 13.2% of all 
reports corresponded to minor nuisances/situations that 
could be resolved by the pharmacist, by means of indica-
tion of OTC medicines; between them, some disturbances 
of gastrointestinal tract (constipation, nauseas, dyspepsia, 
pyrosis, and flatulence), sleeping disturbances, parasitosis 
e mycoses, as well as dermatological disturbances.
Nimmo (1999) affirms that the OTC medicines re-
present 60% of all medications sold within United States, 
which increases the pharmacist’s responsibility in the 
indication, dispensation, and using follow-up of these 
medications. This way, the indication of medications, 
provided they are within their ambit of actuation, could 
be a useful intervention in the care process.
CONCLUSIONS AND RECOMMENDATIONS
In this study, it was found a population with socio-
demographic characteristics that are similar to those of 
other studies population. It was possible to notice that the 
more mentioned diseases were the chronic diseases that 
are common in this age range, and the most mentioned 
medications represented the most utilized therapeutic 
alternatives to treat such diseases. It is important to em-
phasize that the most reported diseases corresponded to 
about 60% of all diseases mentioned by patients, facili-
tating so the training of professionals for the practice of 
pharmaceutical care.
The algic complaints, in conjunction with the state 
of mind and sleeping disturbances, point out the necessity 
to visualize the health-disease process through a more 
embracing mode, understanding health as the expression 
of quality of life. Under this perspective, the care approach 
extrapolates the curative dimension, being necessary to 
look for an integral and holistic focusing.
It is also necessary to mention that the alteration in 
lifestyle should be viewed as an important aspect for health 
promotion and the development of self-care abilities, a 
way to enable people to confront their own health proble-
ms. In this sense, it is important to highlight the role per-
formed by the pharmacist who proposes himself to develop 
the pharmaceutical care, mainly the pharmacotherapeutic 
follow-up. As a health educator, this professional could 
contribute for the adoption of more healthy life habits, 
which could impact on the appearance and/or evolution 
of several chronic diseases in a decisive way, justifying so 
the implementation of this practice in the country.
It is possible to perceive also a great number of un-
controlled health problems, between them the DRPs, whi-
ch require the intervention of a professional; mainly the 
problems related to effectiveness of proposed medicines. 
Several of these problems could be resolved by means 
of measures to be adopted by the pharmacists disposing 
themselves to work in the context of pharmaceutical care 
practice, as for instance, the introduction of non-pharmaco-
logical measures, the implantation of strategies to increase 
the adhesion to pharmacologic and non-pharmacologic tre-
atments, the education about the correct use of medications, 
the health education, the indication of OTC medications 
and, as appropriate, the patients’ forwarding to be evaluated 
by other health professionals; demonstrating so the useful-
ness and resolutive potential of this practice.
The majority of problems verified with the use of 
medicines are not inherent to it, but to the form in which 
medicines are prescribed, dispensed and used, justifying the 
necessity of a reorientation for the pharmaceutical profes-
sion; in other words, it is necessary a change of paradigm, 
with the pharmaceutical professional leaving the position of 
a mere ‘medicine provider’, to become a ‘service provider’ 
having the pharmaceutical care included among his respon-
sibilities, as a service to be provided to public.
In this context, the pharmaceutical care is placed 
as an important strategy for the resolution of a serious 
problem of public health, the morbimortality related to 
the use of medicines; which on the other hand, exerts an 
important impact on the resources addressed to healthcare 
and on the individuals’ quality of life, as well.
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